The Only Forum Helping Biopharma Unlock Access to Cell & Gene Therapies
Recent CGT commercial launches have struggled commercially, hindered by high upfront costs and payer concerns over clinical efficacy and durability. While there remains a pressing need for health system reform, drug developers must adapt their market strategies to ensure commercial success and coverage in the short-term.
The 2nd Cell & Gene Therapy Pricing & Reimbursement Summit is uniting the crucial stakeholders to tackle these challenges, namely commercial-stage drug manufacturers, government authorities, commercial payers, academic and advocacy organisations, and market access service providers.
Be in the room with these stakeholders to progress your market access strategy, forge connections with industry leaders, and leverage key insights across the following themes:
Unpack New State and Federal Policy Innovation
Learn how to adapt to the new administration’s outlook on pricing and reimbursement, evaluate early learnings from the CMMI CGT Access Model, and discover how states are evolving reimbursement pathways to ensure compliance with the new Medicaid Drug Rebate Program Final Rule
Level Up Your Payer Engagement Strategy
Develop meaningful relationships with national and regional payers, map out payer touchpoints through clinical development, and assess opportunities to engage with reinsurance and stop-loss carriers
Prepare Early for Market Access
Bridge the gap between early-phase clinical development and commercialization with effective clinical trial design to meet payer and HTA needs, leverage robust evidence generation and collection to supplement trial data
Drive Forward Coverage & Uptake Rates
Assess the state of reimbursement systems for CGTs administered in the community setting, overcome cross-border, out-of-state coverage challenges, and leverage models from academia to expand access beyond centers of excellence
Put Innovative Payment Models into Practice
Explore recent trends in IPMs being used to mitigate risk and reinforce value, understand the payer perspective on outcome-based agreements, and develop a framework for selecting outcomes
Learn from expert industry leaders, engage in meaningful group discussion, and form business connections with decision makers to scale up your supply chain – whether this is into the clinic, to pivotal studies, or into the market.
Event in Numbers
70+
ATTENDEES
40+
COMPANIES
23
EXPERT SPEAKERS
15
NEW GROUPS SPEAKING
8
COMMERCIAL BIOPHARMA COMPANIES SPEAKING
100%
ALIGNMENT WITH YOUR MARKET ACCESS NEEDS
Who Will You Meet?
The 2nd Cell & Gene Therapy Pricing & Reimbursement Summit is dedicated to progressing market access conversations through multistakeholder collaboration. We attract an audience of industry experts to ignite thought-provoking discussions that lead to long-term, mutually beneficial relationships in a challenging field.
This is the only industry-led forum dedicated to helping biopharma unlock access to cell and gene therapies.
Uniting 70+ leaders across Pricing & Reimbursement, Market Access, Marketing Commercial, Government Affairs, Policy, Real-World Evidence, and HEOR domains, this year’s summit will provide actional insights for all attendees, whether they are looking to establish a market access department, launch successfully, or bolster the commercial performance of in-market therapies.